1Cipriani, A, Furukawa, TA, Salanti, G, Chaimani, A, Atkinson, LZ, Ogawa, Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. The Lancet 2018; 391: 1357–66.
2Kirsch, I, Moore, TJ, Scoboria, A, Nicholls, SS. The Emperor's new drugs: an analysis of antidepressant medication data submitted to the U.S. food and drug administration. Prevention & Treatment 2002; 5: 2–11.
3Khan, A, Khan, S, Walens, G, Kolts, R, Giller, EL. Frequency of positive studies among fixed and flexible dose antidepressant clinical trial: an analysis of the food and Drug Administration summary basis of approval reports. Neuropsychopharmacology 2002; 28: 552–7.
4Kirsch, I, Deacon, BJ, Huedo-Medina, TB, Scoboria, A, Moore, TJ, Hohnson, BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the food and drug administration. PLoS Med 2008; 5: e45–53.
5Kirsch, I. Antidepressants and the placebo effect. Zeitschrift für Psycholgie 2014; 222: 128–34.
6Walsh, BT, Seidman, SN, Sysko, R, Gould, M. Placebo response in studies of major depression. JAMA 2002; 287: 1840–7.
7Parker, G. Beyond major depression. Psychol Med 2005; 35: 467–74.
8Kendler, K. The phenomenology of major depression and the representativeness and nature of DSM criteria. Am J Psychiatry 2016; 173: 771–80.
9Fawcett, J. Reply to Dr Gordon Parker's critique of DSM-5 mood disorders. Acta Psychiatr Scand 2014; 129: 413–4.